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The present study was performed to determine the behavioral effects of 
cholecalciferol treatment at different doses as an adjunctive therapy alone or 
in a combination with low dose of 17β-estradiol on anxiety-like behavior of the 
middle-aged (12–14 months) and old (16–18 months) female rats at 12 weeks 
after ovariectomy. Vitamin D3 supplementation individually (as cholecalciferol at 
doses of 1.0, 2.5 or 5.0 mg/kg/day, s.c.) or in co-administration with 17β-estradiol 
(17β-E2, 0.5 μg/ rat, s.c.) were given to the ovariectomized (OVX) rats of different 
age at 12 weeks after ovariectomy. Anxiety-related state was tested in the elevated 
plus maze (EPM) and light-dark test (LDT), as well behavioral reactivity was 
registered in the open field test (OFT). The results of the study indicated that 
vitamin D3 supplementation at doses of 1.0 or 5.0 mg/kg/day decreased manifes-
tations of anxiety-like profile in the middle-aged or old OVX rats, respectively. 
Vitamin D3 (1.0 mg/kg/day) plus 17β-E2 resulted in more profound anxiolytic-
like effects in the old OVX rats than effects of both drugs administered alone. 
Cholecalciferol (1.0 mg/kg/day, s.c.) in the old OVX rats produced elevated 
estradiol and 25-OH-VD3 levels for these rats as compared to the old OVX females 
treated with solvent.
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1. Introduction
Anxiety disorders are twice common in women than in men and the risk 
increased more during the menopausal transition [1, 2]. Menopause indicates the 
termination of a woman’s reproductive life. It is defined as the permanent cessation 
of menstruation induced by the loss of ovarian follicular activity [2, 3]. Menopause 
represents an important stage in female lives, which is often associated with a 
plethora of complaints and sufferings. Mood disturbances, especially anxiety and 
depression, are commonly associated with menopause [3, 4]. For women, data sug-
gest that estrogens are strongly implicated in the regulation of mood and behavior, 
as well as in the pathophysiology of mood disorders [5–7]. Nowadays, there is a 
strong tendency to increase the duration of living in the whole world, however, the 
median age of programmed termination of a woman’s reproductive life failed to 
alter [5–7]. Thus, majority of women in the aging population lives significant period 
of their lifetime in a postmenopausal state which is clearly associated with very low 
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estrogen levels that could be one of the marked trigger factors for development of 
affective-related disorders [5, 7].
A strategy to alleviate the mood disorders associated with menopause is hor-
monal replacement therapy (HRT) [8]. However, controversial results related to the 
effectiveness of such treatment have been frequently reported [9]. These discrepan-
cies could be associated to various factors, one of them being the time when estro-
gen restitution is initiated after the beginning of menopause [10, 11].
There is a growing interest about the potential of diet and nutrients to 
improve the mental health of the women population and for the treatment of 
psychiatric disorders [10, 11]. In the case of mood disorders, the limitations of 
psychotropic drugs to achieve adequate rates of clinical remission and functional 
recovery have promoted the search for complementary approaches [12–15]. 
Menopausal women are now choosing to take alternate and complementary 
therapies marketed as “natural” treatments that offer the positive health effects 
of estrogens without the unwanted side effects [12, 13]. Among other nutraceuti-
cals, one of such “natural” substances for treatment of affective-related diseases 
could be vitamin D (VD) [14, 15].
VD is a neuroactive secosteroid with well-known skeletal physiological role 
and diverse “non-skeletal” functions in the human body [16, 17]. “Non-skeletal” 
functions of VD are connected with its different range of outcomes in the central 
nervous system, such as neuroplasticity, apoptosis, cell proliferation and differ-
entiation [18, 19]. All functions of VD in the body (classical functions, i.e., effect 
upon calcium-phosphate management and the non-classical ones) are imposed by 
the nuclear VD receptor (VDR), regulating directly the gene expression [20, 21]. 
Nuclear VDR are member of receptors family for transcription factors which are 
activated by numerous ligands [20, 21]. VDR are present in most tissues and cells 
in the body, and within the brain it shows some specificity to the prefrontal cortex, 
hippocampus, cingulate gyrus, thalamus, hypothalamus and substantia nigra [22]. 
This is of relevance as many of those brain regions have been implicated in the 
physiology of affective-related disorders.
Estrogen deficiency effects on affective-related behavior are restricted to certain 
periods of age after ovary removal [23, 24]. Preclinical data suggest that onset age 
of menopause can be important to obtain behavioral positive or negative results. 
Thus, it is of great interest to evaluate the effects of repeated cholecalciferol admin-
istration on anxiety-related behavior in the middle-aged and old female rats with 
long-term estrogen deficiency.
The aim of the present study was to determine if repeated systemic treatment 
with cholecalciferol affects anxiety-like behavior in the middle-aged and old female 
rats after long-term ovariectomy.
2. Materials and methods
2.1 Animals
Female albino Wistar rats (12–14 months, middle-aged rats or 16–18 months, old 
rats, weighing 230–240 or 260–270 g, respectively) from the special biocollection of 
Koltushi vivarium (St. Petersburg, Russia) were used in the present study. All rats 
were allocated in groups and were allowed to accommodate for 1 week in the animal 
house at I.P. Pavlov Institute of Physiology, of the Russian Academy of Sciences, 
before subjecting them to behavioral testing and pharmacological treatments. They 
were provided with a standard pellet diet and were given water ad libitum. The 
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animals were kept at a temperature of 23 ± 2°C and a 12 h light/dark cycle as well as 
a constant relative humidity (50 ± 10%) during all experimental sessions. Female 
rats of different age were randomly separated into experimental groups accordingly 
to their age, including the control groups.
Vitamin D3 and 17β-E2 treatments, as well as anxiety-related tests were carried 
out by double-blind method by using rules of the Health guide for the care and 
use of Laboratory animals (1978) formulated by the National Institute of Health. 
Females of different age were placed in the special room for behavioral trials at least 
1 h prior to the beginning of the experimental sessions which were performed from 
09:00 am to 12:00 am. The experimental protocols of this study were approved by 
the Institutional Animal Ethics Committee of I.P. Pavlov Institute of Physiology, 
Russia (protocol 1095/1 from June 25, 2012).
2.2 Surgery
Long-term ovariectomy surgery was performed as previously described [25]. 
Briefly, middle-aged and old female rats were anesthetized with ketamine (70 mg/
kg b.w.) mixed with xylazine (10 mg/kg b.w.). To avoid inflammation, the rats were 
administered with meloxicam (1 mg/kg b.w.). The fallopian tube was crushed and 
the ovary was removed by cutting. The effectiveness of long-term ovariectomy 
or 17β-estradiol (17β-E2) application was assessed by vaginal smears. The ovari-
ectomized (OVX) females of different age were housed in groups of five in cages 
separated by groups. To assure the long-term absence of estrogens, all rats after 
surgery were remained to the housing facilities for 12 weeks.
2.3 Drug treatments
17β-estradiol, 17β-E2 (Sigma, USA) at low dose of 5.0 μg/rat [7, 26] and vitamin D3  
as cholecalcirefol (Sigma, USA) at several doses (1.0, 2.5 or 5.0 mg/kg) [27] were 
subcutaneously (s.c.) administered once daily starting 14 days prior to the cognitive 
experiments. 17β-E2 was dissolved in sterile sesame oil, VD3was dissolved in 95% 
ethanol solvent, aliquoted and stored at −80°C. The stock of VD3 was dissolved in 
sterile water, resulting in a solution of cholecalciferol with 2% ethanol. All drug 
solutions were freshly prepared before each behavioral testing. 17β-E2 and chole-
calcirefol were injected in a volume of 0.1 ml. The middle-aged OVX females were 
15.5–17.5 months middle-aged at the onset for drug treatments.
The estrogen, 17β-E2 (E-8875, Sigma Chemical Co., St. Louis, MO, USA) was dis-
solved in sterile sesame oil. Cholecalcirefol (C-9756, Sigma Chemical Co., St. Louis, 
MO, USA) was dissolved in 95% ethanol, aliquoted and stored at −80°C. The stock of 
cholecalciferol was diluted in sterile water, resulting in a solution of cholecalciferol with 
2% ethanol. 17β-E2 was injected subcutaneously (s.c. at a dose of 0.5 μg/rat).  
The low dose of 17β-E2 (5.0 μg/rat subcutaneously, s.c.) was chosen from the studies 
performed by Estrada-Camarena and co-workers [26, 28]. Three doses of cholecalciferol 
(1.0, 2.5 or 5.0 mg/kg, s.c.) were chosen from the behavioral study performed by Idrus 
and co-workers [27]. All solutions were freshly prepared before each experimental series. 
All preparations were administered in a volume of 0.1 ml. Following 12 weeks after 
ovariectomy, cholecalciferol, 17β-E2 and oil solvent were injected once daily for 14 days.
2.4 Animal groups
Female rats (middle-aged or old, intact and OVX) were randomly divided into 
24 groups, accordingly to their age, with 8 rats in each group.
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The following experimental groups for the middle-aged and old female rats were 
created in the present study:
1 and 2—middle-aged or old intact female rats + solvent.
3 and 4—middle-aged or old intact female rats + cholecalciferol 1.0 mg/kg 
(middle-aged or old intact − vitamin D3 1.0).
5 and 6—middle-aged or old intact female rats + cholecalciferol 2.5 mg/kg 
(middle-aged or old intact − vitamin D3 2.5).
7 and 8—middle-aged or old intact female rats + cholecalciferol 5.0 mg/kg 
(middle-aged or old intact − vitamin D3 5.0).
9 and 10—middle-aged or old OVX + solvent (middle-aged or old OVX − Sol).
11 and 12—middle-aged or old OVX rats + 17β-E2 (middle-aged or old OVX − 17β-E2).
13 and 14—middle-aged or old OVX rats + cholecalciferol 1.0 mg/kg (middle-
aged or old OVX − vitamin D3 1.0).
15 and 16—middle-aged or old OVX rats + cholecalciferol 2.5 mg/kg (middle-
aged or old OVX − vitamin D3 2.5).
17 and 18—middle-aged or old OVX rats + vitamin D3 5.0 mg/kg (middle-aged 
or old OVX − vitamin D3 5.0).
19 and 20—middle-aged or old OVX rats + cholecalciferol 1.0 mg/kg + 17β-E2 
(middle-aged or old OVX − vitamin D3 1.0 − 17β-E2).
21 and 22—middle-aged or old OVX rats + cholecalciferol 2.5 mg/kg + 17β-E2 
(middle-aged or old OVX − vitamin D3 2.5 − 17β-E2).
23 and 24—middle-aged or old OVX rats + cholecalciferol 5.0 mg/kg + 17β-E2 
(middle-aged or old OVX − vitamin D3 5.0 − 17β-E2).
The treatment period for animals was 14 days, and at the end of the treatment 
period (1 h after the last dose of solvent, vitamin D3 or 17β-E2), all animals were 
subjected to the elevated plus maze (EPM), light-dark test (LDT) and the open field 
test. During testing sessions in all behavioral tests, the control and experimental 
groups of rats were also given with solvent, vitamin D3 or 17β-E2.
2.5 Behavioral tests
2.5.1 Elevated plus maze test
EPM is commonly accepted as standard test of anxiety-like behavior and was 
used to assess anxiety-like behavioral responses [29, 30]. This test is sensitive to 
putative anxiogenic-like and anxiolytic-like drugs [31]. EPM consist of two open 
arms (50 × 10 cm2) and two closed arms (40 × 10 cm2) with a central platform 
(10 × 10 cm2) and elevated 50 cm above the floor level. All female rats from control 
and experimental groups were randomly placed at the center of the EPM and 
allowed them to freely move in the apparatus for 5 min. The number of entries and 
total time spent in open arms were accepted as parameters of anxiolytic-like effects 
of treatments. The apparatus was cleaned with damp cloth after each trial to avoid 
place preference and the influence of olfactory stimuli.
2.5.2 Light/dark test
The apparatus consist of two identical boxes (30 × 40 × 40 cm), one of which with 
white walls and floor and illuminated by a 60 Watt light from above, while the other of 
the box was painted black and had a lid so it was not illuminated [32, 33]. The number 
of entrance and the total time in the light box were registered for 5 min [7]. The increase 
in the number of entrances and the total time in the light box were postulated as mani-
festation of anxiolytic-like effects of treatments. The apparatus was cleaned with damp 
cloth after each trial to avoid place preference and the influence of olfactory stimuli.
5
Behavioral Effects of Vitamin D3 at Estrogen Deficiency in Females of Different Age
DOI: http://dx.doi.org/10.5772/intechopen.82596
2.5.3 Open field test
The effect of cholecalciferol on locomotor, rearing and grooming activities 
was evaluated automatically using an open-field computer-aided controlling 
system as described previously [34]. The apparatus consists of a square platform 
(80.0 cm × 80.0 cm; wall height 36.0 cm). The floor of the platform was divided 
into 16 equal squares of 19.5 cm × 19.5 cm. A video camera fixed at the top, and the 
apparatus was illuminated by a light source of 120 Lux on the ceiling. Each rat was 
placed at the center of the apparatus and allowed to explore freely for 5 min. Total 
number of central and peripheral square crossings were recorded for each animal. 
The apparatus was cleaned with damp cloth after each trial to avoid place prefer-
ence and the influence of olfactory stimuli.
2.6  Determination of estradiol, 25-OH-VD3 and calcium levels in the  
blood serum
Blood samples were collected in tubes and centrifuged. After centrifugation, 
serum was separated, frozen and stored at −20°C until biochemical assess-
ment. Estradiol levels were assessed using commercial available ELISA kit 
(DRG Diagnostics, Marburg, Germany). The sensitivity of the estradiol ELISA 
kit was 1.0 pg/ml. Measurement of 25-hydroxyvitamin D3 (25-OH-VD3) levels 
was performed by ELISA kit (CSB-E08098r, Cusabio Biotech Co., Ltd., Wuhan, 
P.R. China). Technical variability for 25-OH-VD3 ELISA kit was low with coef-
ficients of variation of <10% intra-assay and < 15% inter-assay. Detection range of 
25-OH-VD3 levels was 20–100 μg/L. The sensitivity of the 25-OH-VD3 using ELISA 
kit was 5.0 μg/L. Calcium concentrations were detected by spectrophotometric 
method using calcium assay colorimetric kit (ab102505, Abcam, France). The sen-
sitivity of the calcium kit was 0.1 m/M. All the procedures of estradiol, 25-OH-VD3 
and calcium kits were conducted following the manufacturer’s instruction manual.
2.7 Statistical analysis
Data were expressed as means ± standard error (SEM). Differences among 
means were postulated as significant at р ≤ 0.05. Behavioral and biochemical data 
were analyzed using a two-way ANOVA and subsequent post-hoc analysis was con-
ducted with Dunnett’s multiple comparison test. Statistical calculation was carried 
out using SPSS software 19 version (SPSS Inc., Chicago, IL., USA).
3. Results
3.1  Vitamin D3 in different doses decreases anxiety-like profile of the  
middle-aged and old OVX and OVX rats given with 17β-estradiol after  
long-term absence of estrogen as measured in the EPM test
For vitamin D3 supplementation, two-way ANOVA analysis revealed a signifi-
cant interaction between hormone condition and treatments ([F(5,44) = 12.83, 
p < 0.05] and [F(5,44) = 9.47, p < 0.01], respectively), with significant effects of 
hormone conditions ([F(5,44) = 9.47, p < 0.01 and [F(5,44) = 7.88, p < 0.01], respec-
tively) and treatment ([F(5,44) = 15.24, p < 0.05] and [F(5,44) = 11.02, p < 0.05], 
respectively) in the time spent into the open arms or the number of entries into the 
open arms of the middle-aged OVX rats. The post-hoc test demonstrated significant 
differences for these groups (p < 0.05).
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Vitamin D3 application at all tested doses did not modify the time spent into the 
open arms and the number of entries into the open arms in the intact middle-aged 
rats as compared to the control rats (Figure 1a, b, p > 0.05). Following 12 weeks 
of post-surgery period, the middle-aged female rats showed a profound decrease 
of the time spent in the open arms and the number of entries into the open arms 
as compared to the control females (Figure 1a, b, p < 0.05). The 17β-E2 injection 
(0.5 μg/kg, s.c.) resulted in an increase of the time spent in the open arms and the 
number of entries into the open arms in the middle-aged OVX rats as compared to 
the middle-aged OVX rats administered with solvent (Figure 1a, b, p < 0.05), but 
did not reach the values of control rats (Figure 1a, b, p < 0.05).
Vitamin D3 treatment at dose of 5.0 mg/kg significantly increased the time 
spent in the open arms and the number of entries into the open arms of the mid-
dle-aged OVX rats as compared to the middle-aged OVX rats given with solvent 
(Figure 1a, b, p > 0.05). Co-administration of vitamin D3 at dose of 5.0 mg/kg  
and 17β-E2 to the middle-aged OVX rats produced a more greater increase of the 
time spent in the open arms and the number of entries into the open arms than 
that of the middle-aged OVX rats given 17β-E2 or solvent (Figure 1a, b, p > 0.05). 
However, vitamin D3 treatment at doses of 1.0 and 2.5 mg/kg individually or plus 
17β-E2 failed to alter the time spent in the open arms and the number of entries 
Figure 1. 
Effects of cholecalciferol administration on anxiety-like behavior of the middle-aged ovariectomized (OVX) 
rats following long-term estrogen deficiency in the elevated plus maze. (a) Time spent into the open arms, 
sec; (b) The number of entries into the open arms. The obtained results show the mean ± standard error of 
the mean (SEM). *—p < 0.05 as compared to the control group of the old sham-operated rats; #—p < 0.05 as 
compared to the old OVX rats treated with solvent; ##—p < 0.05 as compared to the old OVX rats treated with 
17β-estradiol (17β-E2). Each group comprised a minimum of eight rats. Cholecalciferol was given at 1.0, 2.5 or 
5.0 mg/kg/day subcutaneously (s.c.), once daily, for 14 days. The administered dose of 17β-estradiol was  
0.5 μg/rat s.c., once daily, for 14 days.
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into the open arms of the middle-aged OVX as compared to the middle-aged OVX 
rats treated with 17β-E2 Figure 1a, b, p > 0.05). The time spent in the open arms 
and the number of entries into the open arms in the middle-aged OVX rats admin-
istered with vitamin D3 at these doses in combination with 17β-E2 were lower than 
that for middle-aged control rats and were higher than for middle-aged OVX rats 
(Figure 1a, b, p > 0.05).
Two-way ANOVA test demonstrated a significant hormone condition × treat-
ment interaction ([F(5,44) = 11.44, p < 0.05] and [F(5,44) = 11.12, p < 0.01], 
respectively), significant effect of hormone conditions ([F(5,44) = 9.22, p < 0.01] 
and [F(5,44) = 16.88, p < 0.01], respectively) and significant effect for treatment 
([F(5,44) = 11.56, p < 0.05], and [F(5,44) = 12.56, p < 0.05], respectively) for the 
time spent into the open arms or the number of entries into the open arms of the old 
OVX rats. Post-hoc analyses revealed differences among the groups for the anxiety-
like state during experimental sessions (p < 0.05).
The old intact rats treated with vitamin D3 at doses of 1.0, 2.5 or 5.0 mg/kg failed 
to alter the time spent into the open arms and the number of entries into the open 
arms as compared to the old control rats (Figure 2a, b, p > 0.05). The old OVX rats 
given with solvent displayed a significant decrease of the time spent into the open 
arms and the number of entries into the open arms as compared to the old control 
rats (Figure 2a, b, p > 0.05).
Figure 2. 
Effects of cholecalciferol administration on anxiety-like behavior of the old ovariectomized (OVX) rats 
following long-term estrogen deficiency in the elevated plus maze. (a) Time spent into the open arms, sec; 
(b) The number of entries into the open arms. The obtained results show the mean ± standard error of the 
mean (SEM). *—p < 0.05 as compared to the control group of the old sham-operated rats; #—p < 0.05 as 
compared to the old OVX rats treated with solvent; ##—p < 0.05 as compared to the old OVX rats treated with 
17β-estradiol (17β-E2). Each group comprised a minimum of eight rats. Cholecalciferol was given at 1.0, 2.5 or 
5.0 mg/kg/day subcutaneously (s.c.), once daily, for 14 days. The administered dose of 17β-estradiol was  
0.5 μg/rat s.c., once daily, for 14 days.
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Vitamin D3 supplementation administered in all doses to the old OVX rats 
resulted in increase of the time spent into the open arms and the number of entries 
into the open arms as compared to the old OVX rats treated with solvent (Figure 2a, b, 
p > 0.05). Combined administration of cholecalciferol at dose of 1.0 mg/kg with 
17β-E2 to the old OVX rats more significantly increased the time spent into the open 
arms and the number of entries into the open arms as compared to the old OVX rats 
treated with solvent or 17β-E2 (Figure 2a, b, p > 0.05). The old OVX rats adminis-
tered with cholecalciferol at doses of 2.5 mg/kg and 5.0 mg/kg plus 17β-E2 showed 
similar values of the time spent into the open arms and the number of entries into 
the open arms like as old OVX rats treated with 17β-E2 (Figure 2a, b, p > 0.05).
3.2 Vitamin D3 at different doses reverses anxiety-like profile of the middle-aged 
and old OVX and OVX rats given with 17β-estradiol after long-term absence 
of estrogen as measured in light: dark box
Two-way ANOVA statistical test revealed a significant interaction between 
hormone condition and treatments ([F(5,44) = 11.52, p < 0.01) and [F(5,44) = 16.75, 
p < 0.05], respectively), with significant effects of hormone conditions 
([F(5,44) = 19.22, p < 0.05 and [F(5,44) = 9.56, p < 0.001], respectively) and treat-
ment ([F(5,44) = 9.88, p < 0.01] and [F(5,32) = 7.26, p < 0.05], respectively) in the 
time spent and number of entries in the light compartment of the middle-aged OVX 
rats. The post-hoc test demonstrated significant differences for these groups (p < 0.05).
Vitamin D3 supplementation at all doses did not alter the time spent and number 
of entries in the light compartment in the intact middle-aged rats as compared to 
the control rats (Figure 3a, b, p > 0.05). Following 12 weeks of post-ovariectomy 
period, the middle-aged female rats showed a profound decrease of the time spent 
and number of entries in the light compartment as compared to the control females 
(Figure 3a, b, p < 0.05). The 17β-E2 injection (0.5 μg/kg, s.c.) resulted in an increase 
of the time spent and number of entries in the light compartment in the middle-
aged OVX rats as compared to the middle-aged OVX rats administered with solvent 
(Figure 3a, b, p < 0.05), but did not reach the values of control rats (Figure 3a, b,  
p < 0.05).
Vitamin D3 treatment at dose of 5.0 mg/kg markedly elevated time spent and 
number of entries in the light compartment of the middle-aged OVX rats as com-
pared to the middle-aged OVX rats given with solvent (Figure 3a, b, p > 0.05). 
Co-administration of vitamin D3 at dose of 5.0 mg/kg and 17β-E2 to the middle-aged 
OVX rats produced greater increase of time spent and number of entries in the light com-
partment than that of the middle-aged OVX rats given 17β-E2 or solvent (Figure 3a, b,  
p > 0.05). Vitamin D3 treatment at doses of 1.0 mg/kg and 2.5 mg/kg individually or 
plus 17β-E2 did not change time spent and number of entries in the light compart-
ment of the middle-aged OVX as compared to the middle-aged OVX rats treated 
with 17β-E2 (Figure 3a, b, p > 0.05). The time spent and number of entries in the 
light compartment in the middle-aged OVX rats administered vitamin D3 at these 
doses in combination with 17β-E2 were lower than that for middle-aged control rats 
and were higher than for middle-aged OVX rats (Figure 3a, b, p > 0.05).
Two-way analysis of variance showed a significant hormone condition × treat-
ment interaction ([F(5,44) = 11.52, p < 0.01] and [F(5,44) = 12.74, p < 0.05], 
respectively), significant effect of hormone conditions ([F(5,44) = 11.22, p < 0.05] 
and [F(5,44) = 11.56, p < 0.001], respectively) and significant effect for treatment 
([F(5,44) = 10.08, p < 0.01] and [F(5,32) = 12.26, p < 0.05)], respectively) for time 
spent and number of entries in the light compartment of the old OVX rats. Post-hoc 
analyses revealed differences among the groups for the anxiety-like state during 
experimental sessions (p < 0.05).
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The old intact rats treated with vitamin D3 at doses of 1.0, 2.5 or 5.0 mg/kg 
failed to modify time spent and number of entries in the light compartment as 
compared to the old control rats (Figure 4a, b, p > 0.05). The old OVX rats given 
with solvent displayed a significant decrease of time spent and number of entries in 
the light compartment as compared to the old control rats (Figure 4a, b, p > 0.05).
Vitamin D3 supplementation administered in all doses to the old OVX rats 
induced increase of the time spent and number of entries in the light compartment 
as compared to the old OVX rats treated with solvent (Figure 4a, b, p > 0.05). 
Combined administration of cholecalciferol at dose of 1.0 mg/kg with 17β-E2 to the 
old OVX rats more significantly increased time spent and number of entries in the 
light compartment as compared to the old OVX rats treated with solvent or 17β-E2 
(Figure 4a, b, p > 0.05). The old OVX rats administered with vitamin D3 at doses of 
2.5 mg/kg and 5.0 mg/kg plus 17β-E2 showed identical parameters of time spent and 
number of entries in the light compartment like as old OVX rats treated with 17β-E2 
(Figure 4a, b, p > 0.05).
3.3 Vitamin D3 administration changes behavioral reactivity of the middle-aged 
and old OVX and OVX rats treated with 17β-estradiol
Accordingly to the two-way ANOVA test, there were significant differences for 
the grooming behavior between hormone conditions ([F(5,44) = 8.12, p < 0.05] and 
[F(5,44) = 9.22, p < 0.05], respectively) between drug treatment ([F(5,44) = 12.51, 
Figure 3. 
Effects of cholecalciferol administration on anxiety-like behavior of the middle-aged OVX rats following long-
term estrogen deficiency in the light/dark test. (a) Time spent in the light box, sec; (b) The number of entrances 
in the light box. The obtained results show the mean ± standard error of the mean (SEM). *—p < 0.05 as 
compared to the control group of sham-operated rats, #—p < 0.05 as compared to the old OVX rats treated 
with solvent, ##—p < 0.05 as compared to the old OVX rats treated with 17β-estradiol. Each group comprised 
a minimum of eight rats. Cholecalciferol was given at 1.0, 2.5 or 5.0 mg/kg/day s.c., once daily, for 14 days. The 
administered dose of 17β-estradiol (17β-E2) was 0.5 μg/rat s.c., once daily, for 14 days.
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p < 0.01] and [F(5,44) = 12.56, p < 0.01], respectively) and an interaction between 
hormone condition and treatments ([F(5,44) = 7.16, p < 0.01] and [F(5,44) = 9.26, 
p < 0.01], respectively) in the middle-aged and old OVX rats. Further post-hoc test 
revealed differences for grooming between experimental groups of the OVX rats 
with different age (p < 0.05).
Vitamin D3 injected at several doses failed to demonstrate any changes of behav-
ioral reactivity of the middle-aged and old intact females in the OFT as compared to 
the middle-aged control rats (Tables 1 and 2, p > 0.05).
A significant decrease of grooming behavior was registered in the middle-aged 
and old OVX rats given with solvent as compared to the control (Tables 1 and 2, 
p < 0.05). 17β-E2 significantly reduced grooming reactions in the middle-aged and 
old OVX rats as compared to the middle-aged OVX rats (Tables 1 and 2, p < 0.05). 
The middle-aged and old OVX rats treated with vitamin D3 in all tested doses alone 
or in a combination with 17β-E2 did not demonstrate any modifications of motor 
and rearing activities as compared to the middle-aged OVX rats given with solvent 
(Tables 1 and 2, p < 0.05).
However, the middle-aged and old OVX rats treated with vitamin D3 at doses of 
1.0, 2.5 and 5.0 mg/kg demonstrated an increase of grooming behavior as compared 
to the middle-aged OVX rats. A co-administration of vitamin D3 at these doses with 
17β-E2 decreased grooming behavior as compared to both middle-aged, as well as 
old intact and OVX rats received with solvent or 17β-E2 (Tables 1 and 2, p < 0.05).
Figure 4. 
Effects of cholecalciferol administration on anxiety-like behavior of the old OVX rats following long-term 
estrogen deficiency in the light/dark test. (a) Time spent in the light box, sec; (b) The number of entrances 
in the light box. The obtained results show the mean ± standard error of the mean (SEM). *—p < 0.05 as 
compared to the control group of sham-operated rats, #—p < 0.05 as compared to the old OVX rats treated 
with solvent, ##—p < 0.05 as compared to the old OVX rats treated with 17β-estradiol. Each group comprised 
a minimum of eight rats. Cholecalciferol was given at 1.0, 2.5 or 5.0 mg/kg/day s.c., once daily, for 14 days. The 
administered dose of 17β-estradiol (17β-E2) was 0.5 μg/rat s.c., once daily, for 14 days.
11
Behavioral Effects of Vitamin D3 at Estrogen Deficiency in Females of Different Age
DOI: http://dx.doi.org/10.5772/intechopen.82596
3.4 Modifications of 25-hydroxyvitamin D3, estradiol and calcium levels in the 
blood serum following vitamin D3 administration in the middle-aged and old 
OVX and OVX females treated with 17β-estradiol
The middle-aged intact rats treated with cholecalciferol at doses of 1.0, 2.5 and 
5.0 mg/kg increased 25-OH-VD3 levels (Figure 5, p < 0.05) and failed to alter estra-
diol levels in the serum blood as compared to the control rats (Figure 6, p > 0.05).
Long-term ovariectomy in the middle-aged female rats resulted in a significant 
decrease of estradiol and 25-OH-VD3 levels in the blood as compared to the middle-
aged control females (Figures 5 and 6, p < 0.05). The 17β-E2 supplementation 
(0.5 μg/kg, SC) failed to modify 25-OH-VD3 levels in the blood of the middle-
aged OVX rats as compared to the middle-aged OVX rats administered with 
solvent (Figure 5, p > 0.05), and the value of this parameter in the middle-aged 
OVX/17β-E2 females were lower than that of the value of middle-aged control rats. 
However, 17β-E2 supplementation significantly increased estradiol levels in the 
blood of the middle-aged OVX rats as compared to the middle-aged OVX rats given 
with solvent (Figure 6, p < 0.05).
The middle-aged OVX rats treated with cholecalciferol at all tested doses signifi-
cantly increased estradiol levels in the serum blood as compared to the middle-aged 
OVX rats treated with solvent (Figure 6, p < 0.05). However, the value of estradiol 
levels in the middle-aged OVX rats treated with cholecalciferol at these doses were 
lower than that of the value of middle-aged control rats. The middle-aged OVX rats 
treated with cholecalciferol at doses of 2.5 and 5.0 mg/kg significantly increased 
25-OH-VD3 levels in the serum blood as compared to the middle-aged OVX rats 
Groups Crossing Rearing Grooming
Middle-aged control rats + solvent 73.3 ± 4.2 12.1 ± 0.8 3.0 ± 0.2
Middle-aged intact rats + cholecalciferol 1.0 mg/kg 68.0 ± 2.4 12.0 ± .05 3.2 ± 0.2
Middle-aged intact rats + cholecalciferol 2.5 mg/kg 59.3 ± 5.6 10.5 ± 0.8 3.2 ± 0.2
Middle-aged intact rats + cholecalciferol 5.0 mg/kg 69.5 ± 4.2 11.7 ± 0.8 3.5 ± 0.2
Middle-aged OVX rats + solvent (OVX/solvent rats) 62.4 ± 2.3 12.3 ± 0.6 1.2 ± 0.5*
Middle-aged OVX rats +17β-E2 (OVX/17β-E2 rats) 60.3 ± 2.6 13.2 ± 0.3 3.3 ± 0.4
#
Middle-aged OVX rats + cholecalciferol 1.0 mg/kg 65.2 ± 2.5 12.1 ± 0.6 4.0 ± 0.2#
Middle-aged OVX rats + cholecalciferol 2.5 mg/kg 76.9 ± 4.2 13.2 ± 0.8 3.8 ± 0.4#
Middle-aged OVX rats + cholecalciferol 5.0 mg/kg 72.3 ± 4.4 11.0 ± 0.5 4.1 ± 0.6#
Middle-aged OVX rats + cholecalciferol 1.0 mg/
kg + 17β-E2
62.1 ± 2.8 12.6 ± 0.6 0.6 ± 0.2*,#,##
Middle-aged OVX rats + cholecalciferol 2.5 mg/
kg + 17β-E2
73.2 ± 2.4 10.2 ± 0.4 0.5 ± 0.2*,#,##
Middle-aged OVX rats + cholecalciferol 5.0 mg/
kg + 17β-E2
65.4 ± 5.6 12.5 ± 0.8 0.8 ± 0.2*,#,##
*p < 0.05 as compared to the control group of the old sham-operated rats.
#p < 0.05 as compared to the old OVX rats treated with solvent.
##p < 0.05 as compared to the old OVX rats treated with 17β-estradiol.
The obtained results show the mean ± S.E.M. Each group comprised a minimum of eight rats. Cholecalciferol was 
given at 1.0, 2.5 or 5.0 mg/kg/day, s.c., once daily, for 14 days. 17β-Estradiol (17β-E2) was given at 0.5 μg/rat, s.c., 
once daily, during 14 days.
Table 1. 
Cholecalciferol influences on behavioral parameters of the middle-aged OVX rats following long-term estrogen 
deficiency in the open field test for 5 min.
Fads and Facts about Vitamin D
12
treated with solvent (Figure 5, p < 0.05). The value of 25-OH-VD3 content in the 
middle-aged OVX rats treated with cholecalciferol at doses of 2.5 and 5.0 mg/kg 
were lower than that of the value of middle-aged control rats. Moreover, cholecal-
ciferol administered at a dose of 1.0 mg/kg into the middle-aged OVX rats failed to 
change 25-OH-VD3 levels in the serum blood as compared to the middle-aged OVX 
rats treated with solvent (Figure 5, p > 0.05). Cholecalciferol treatment at doses of 
Figure 5. 
Effects of cholecalciferol administration on 25-OH-VD3 level of the middle-aged ovariectomized (OVX) rats 
following long-term estrogen deficiency in the serum blood. The obtained results show the mean ± standard 
error of the mean (SEM). *—p < 0.05 as compared to the control group of the old sham-operated rats; 
#—p < 0.05 as compared to the old OVX rats treated with solvent; ##—p < 0.05 as compared to the old OVX 
rats treated with 17β-estradiol (17β-E2). Each group comprised a minimum of eight rats. Cholecalciferol 
was given at 1.0, 2.5 or 5.0 mg/kg/day subcutaneously (s.c.), once daily, for 14 days. The administered dose of 
17β-estradiol was 0.5 μg/rat s.c., once daily, for 14 days.
Groups Crossing Rearing Grooming
Old control rats + solvent 69.7 ± 5.2 11.5 ± 0.3 2.9 ± 0.2
Old intact rats + cholecalciferol 1.0 mg/kg 71.8 ± 2.9 10.7 ± 0.3 3.2 ± 0.2
Old intact rats + cholecalciferol 2.5 mg/kg 66.9 ± 3.6 10.4 ± 0.2 3.1 ± 0.2
Old intact rats + cholecalciferol 5.0 mg/kg 69.0 ± 4.2 12.2 ± 0.8 3.0 ± 0.2
Old OVX rats + solvent (OVX/solvent rats) 72.1 ± 2.3 12.1 ± 0.6 1.0 ± 0.2*
Old OVX rats + 17β-E2 (OVX/17β-E2 rats) 64.3 ± 4.6 11.7 ± 0.8 3.1 ± 0.3
#
Old OVX rats + cholecalciferol 1.0 mg/kg 63.2 ± 3.5 12.6 ± 0.9 4.2 ± 0.2#
Old OVX rats + cholecalciferol 2.5 mg/kg 67.2 ± 5.2 10.2 ± 0.8 3.9 ± 0.2#
Old OVX rats + cholecalciferol 5.0 mg/kg 70.3 ± 4.4 11.5 ± 0.5 4.3 ± 0.2#
Old OVX rats + cholecalciferol 1.0 mg/kg + 17β-E2 72.1 ± 6.8 12.2 ± 0.6 0.7 ± 0.2
*,#,##
Old OVX rats + cholecalciferol 2.5 mg/kg + 17β-E2 78.5 ± 8.4 11.8 ± 0.4 0.6 ± 0.2
*,#,##
Old OVX rats + cholecalciferol 5.0 mg/kg + 17β-E2 69.4 ± 6.6 10.9 ± 0.8 0.9 ± 0.2
*,#,##
*p < 0.05 as compared to the control group of the old sham-operated rats.
#p < 0.05 as compared to the old OVX rats treated with solvent.
##p < 0.05 as compared to the old OVX rats treated with 17β-estradiol.
The obtained results show the mean ± S.E.M. Each group comprised a minimum of 8 rats. Cholecalciferol was given 
at 1.0, 2.5 or 5.0 mg/kg/day, s.c., once daily, for 14 days. 17β-Estradiol (17β-E2) was given at 0.5 μg/rat, s.c., once 
daily, during 14 days.
Table 2. 
Effects of cholecalciferol administration on behavioral impairments of the old OVX rats following long-term 
estrogen deficiency in the open field test for 5 min.
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2.5 and 5.0 mg/kg in combination with 17β-E2 more significantly elevated 25-OH-
VD3 levels for the middle-aged OVX rats as compared to the OVX females treated 
with oil solvent or 17β-E2 (Figure 3, p < 0.05). Combined administration of chole-
calciferol at a dose of 1.0 mg/kg and 17β-E2 in the middle-aged OVX rats failed to 
change 25-OH-VD3 levels as compared to the OVX rats administered with 17β-E2 or 
solvent (Figure 5, p > 0.05). Cholecalciferol at all doses in combination with 17β-E2 
significantly increased estradiol levels when middle-aged OVX rats/cholecalciferol 
in tested doses plus 17β-E2 rats were compared with the middle-aged OVX/solvent 
and OVX/17β-E2 rat groups (Figure 6, p > 0.05).
The old intact rats treated with cholecalciferol at doses of 1.0, 2.5 and 5.0 mg/kg 
increased 25-OH-VD3 levels (Figure 7, p < 0.05) and failed to alter estradiol levels 
in the serum blood as compared to the control rats (Figure 8, p > 0.05). Long-term 
ovariectomy in the old female rats resulted in a significant decrease of estradiol and 
25-OH-VD3 levels in the blood as compared to the old control females (Figures 7  
and 8, p < 0.05). The 17β-E2 supplementation (0.5 μg/kg, s.c.) failed to modify 
Figure 6. 
Effects of cholecalciferol administration on estradiol level of the middle-aged ovariectomized (OVX) rats 
following long-term estrogen deficiency in the serum blood. The obtained results show the mean ± standard 
error of the mean (SEM). *—p < 0.05 as compared to the control group of the old sham-operated rats; 
#—p < 0.05 as compared to the old OVX rats treated with solvent; ##—p < 0.05 as compared to the old OVX 
rats treated with 17β-estradiol (17β-E2). Each group comprised a minimum of eight rats. Cholecalciferol 
was given at 1.0, 2.5 or 5.0 mg/kg/day subcutaneously (s.c.), once daily, for 14 days. The administered dose of 
17β-estradiol was 0.5 μg/rat s.c., once daily, for 14 days.
Figure 7. 
Effects of cholecalciferol administration on 25-OH-VD3 level of the old ovariectomized (OVX) rats following 
long-term estrogen deficiency in the serum blood. The obtained results show the mean ± standard error of the 
mean (SEM). *—p < 0.05 as compared to the control group of the old sham-operated rats; #—p < 0.05 as 
compared to the old OVX rats treated with solvent; ##—p < 0.05 as compared to the old OVX rats treated with 
17β-estradiol (17β-E2). Each group comprised a minimum of eight rats. Cholecalciferol was given at 1.0, 2.5 or 
5.0 mg/kg/day subcutaneously (s.c.), once daily, for 14 days. The administered dose of 17β-estradiol was 0.5 μg/rat s.c., 
once daily, for 14 days.
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25-OH-VD3 levels in the blood of the old OVX rats as compared to the old OVX rats 
administered with solvent (Figure 7, p > 0.05), and the value of this parameter in 
the old OVX/17β-E2 females were lower than that of the value of old control rats. 
However, 17β-E2 supplementation significantly increased estradiol levels in the blood 
of the old OVX rats as compared to the old OVX rats given with solvent (Figure 8, 
p < 0.05).
The old OVX rats treated with cholecalciferol at all doses significantly increased 
25-OH-VD3 and estradiol levels in the serum blood as compared to the old OVX rats 
treated with solvent (Figure 8, p < 0.05). However, the values of 25-OH-VD3 and 
estradiol levels in the old OVX rats treated with cholecalciferol at all doses were 
lower than that of the values of old control rats.
Co-administration of vitamin D3 (1.0 mg/kg) and 17β-E2 markedly enhanced 
estradiol levels in the old OVX rats as compared to the groups of old OVX rats 
received with solvent or 17β-E2 (Figure 7, p < 0.05). Vitamin D3 supplementation 
(2.5 and 5.0 mg/kg) plus 17β-E2 did not modify estradiol concentrations in the 
serum blood of the old OVX rats as compared to the OVX rats given with 17β-E2 
Figure 8. 
Effects of cholecalciferol administration on estradiol level of the old ovariectomized (OVX) rats following 
long-term estrogen deficiency in the serum blood. The obtained results show the mean ± standard error of the 
mean (SEM). *—p < 0.05 as compared to the control group of the old sham-operated rats; #—p < 0.05 as 
compared to the old OVX rats treated with solvent; ##—p < 0.05 as compared to the old OVX rats treated with 
17β-estradiol (17β-E2). Each group comprised a minimum of eight rats. Cholecalciferol was given at 1.0, 2.5 or 
5.0 mg/kg/day subcutaneously (s.c.), once daily, for 14 days. The administered dose of 17β-estradiol was 0.5 μg/rat s.c.,  
once daily, for 14 days.
Figure 9. 
Effects of cholecalciferol administration on calcium level of the middle-ged ovariectomized (OVX) rats 
following long-term estrogen deficiency in the serum blood. The obtained results show the mean ± standard 
error of the mean (SEM). *—p < 0.05 as compared to the control group of the old sham-operated rats; 
#—p < 0.05 as compared to the old OVX rats treated with solvent; ##—p < 0.05 as compared to the old OVX 
rats treated with 17β-estradiol (17β-E2). Each group comprised a minimum of eight rats. Cholecalciferol 
was given at 1.0, 2.5 or 5.0 mg/kg/day subcutaneously (s.c.), once daily, for 14 days. The administered dose of 
17β-estradiol was 0.5 μg/rat s.c., once daily, for 14 days.
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(Figure 7, p > 0.05). Cholecalciferol at all doses in combination with 17β-E2 signifi-
cantly increased 25-OH-VD3 levels when these old OVX rats were compared with 
the old OVX/solvent and OVX/17β-E2 groups (Figure 8, p > 0.05).
The two-way ANOVA failed to show any significant differences in the calcium 
levels in the blood serum between hormone conditions, drug treatments, and an 
interaction between hormone condition and treatments in the middle-aged and old 
OVX rats with long-term estrogen deficiency (Figures 9 and 10, p > 0.05). The post-
hoc test did not find any differences among the experimental groups for the calcium 
levels (p > 0.05).
4. Discussion
In the present study, the effects of chronic cholecalciferol treatment at differ-
ent doses (1.0, 2.5 and 5.0 mg/kg, s.c.) for 14 days on anxiety-like behavior in the 
middle-aged and old female rats with long-term estrogen deficiency and 17β-E2 sup-
plementation in a low dose were examined. Endogenous estrogens were removed 
by ovariectomy and only after 12 weeks post-ovariectomy period, these rats were 
used in all experiments. The results of behavioral testing for the anxiety-related 
effects of cholecalciferol were compared in both old OVX rats and OVX female rats 
treated with 17β-E2. Simultaneously, the effects of cholecalciferol at similar doses on 
anxiety-like behavior were tested in middle-aged and old intact female rats. For this 
purpose, the elevated plus maze (EPM) and light-dark test (LDT) were made use 
in the present study. It was also investigated whether the effects of cholecalciferol 
at different doses were specific in the EPM and LDT, measuring its effects on the 
behavioral activity in the OFT of the middle-aged and old intact and OVX rats after 
long-term absence of estrogen.
Cholecalciferol at all investigated doses did not produce any changes of anxiety-like 
behavior of the middle-aged and old intact female rats in the EPM and LDT. Analyzing 
the results from biochemical assay, an increase of 25-OH-VD3 concentrations and 
absence of any modifications of estradiol levels in the serum blood of the middle-aged 
and old intact rats given with different doses of cholecalciferol were found.
These results suggest that cholecalciferol induced the increasing of 25-OH-VD3 
levels in the blood serum of the middle-aged and old intact-ovary rats are not 
associated with absence of anxiety-like profile alterations in the behavioral tests. 
Figure 10. 
Effects of cholecalciferol administration on calcium level of the old ovariectomized (OVX) rats following 
long-term estrogen deficiency in the serum blood. The obtained results show the mean ± standard error of the 
mean (SEM). *—p < 0.05 as compared to the control group of the old sham-operated rats; #—p < 0.05 as 
compared to the old OVX rats treated with solvent; ##—p < 0.05 as compared to the old OVX rats treated with 
17β-estradiol (17β-E2). Each group comprised a minimum of eight rats. Cholecalciferol was given at 1.0, 2.5 or 
5.0 mg/kg/day subcutaneously (s.c.), once daily, for 14 days. The administered dose of 17β-estradiol was 0.5 μg/
rat s.c., once daily, for 14 days.
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Furthermore, the ovary-intact female rats of different age are also needed to evalu-
ate the behavioral effects of cholecalciferol administered at several doses in the 
EPM and LDT paradigms.
The results showed that in the middle-aged and old OVX rats following 12 weeks 
of post-ovariectomy period, there were marked anxiety-like behavior as assessed by 
EPM and LDT. Although 17β-E2 supplementation resulted in significant anxiolytic-
like effect of the middle-aged and old OVX rats with long-term absence of estrogen, 
the 17β-E2 administration was not able to completely diminish anxiety-like behavior 
to the level of the middle-aged and old control intact animals. According to these 
results, we conclude that middle-aged and old OVX rats following 12 weeks of 
postovariectomy period display significant anxiety-related behavior, while 17β-
E2 administration to the middle-aged and old OVX rats attenuates the estrogen 
deficiency-induced anxiety-like behavior to some extent. In fact, these experiments 
showed that the effects of 17β-E2 supplementation on anxiety-like behavior did not 
associated with absence of its effects on 25-OH-VD3 levels in the old OVX rats. The 
long-term effect of ovariectomy on anxiety-like behavior in female rats of different 
age that were submitted in a standard behavioral tests [24, 35, 36].
Cholecalciferol at dose of 5.0 mg/kg/day per se had a significant anxiolytic-
like effect in the middle-aged OVX rats following long-term ovariectomy. On the 
contrary, cholecalciferol at doses of 1.0 and 2.5 mg/kg/day failed to induce any 
modifications of anxiety-like behavior in the middle-aged OVX rats with  
long-term absence of estrogen. Combined application of vitamin D3 (1.0 mg/kg/day) 
with 17β-E2-induced synergic anxiolytic-like action of both preparations in the 
anxiety-related tasks of the old OVX rats. Cholecalciferol at all doses per se had a 
significant anxiolytic-like effect in the old OVX rats following long-term ovari-
ectomy. Unexpectedly, that the old OVX rats with 12 weeks post-ovariectomy 
period administered with cholecalciferol at doses 2.5 and 5.0 mg/kg/day in 
combination with 17β-E2 showed similar anxiety-like profile like the OVX rats 
given with 17β-E2. Thus, we did not observe any synergic anxiolytic-like effects 
of cholecalciferol at doses of 2.5 or 5.0 mg/kg in the old OVX rats given with 
17β-E2. It might suppose that there are some concurrent relation between 17β-E2 
and cholecalciferol at doses of 2.5 and 5.0 mg/kg/day. In fact, application of 
17β-E2 interfere with anxiolytic-like action of cholecalciferol at doses of 2.5 or 
5.0 mg/kg in the old OVX rats after long-term ovariectomy. Simultaneously, 
cholecalciferol treatment in all tested doses similarly increased grooming, did 
not change locomotor activity and rearing of the middle-aged and old OVX rats 
after long-term ovariectomy. Thus, the present results suggest that anxiolytic-
like effects of vitamin D3 are specific in the OVX rats of different age given with 
solvent or 17β-E2, since data of the OFT were not able to demonstrate any of 
alterations in motor or rearing activities in these rats. Combined application of 
vitamin D3 (5.0 mg/kg/day) with low dose of 17β-E2 synergistically decreased 
anxiety-like profile of the middle-aged OVX rats. However, vitamin D3 at all 
doses significantly decreased grooming behavior in the middle-aged OVX rats 
treated with 17β-E2.
Unexpectedly, the middle-aged OVX rats treated with vitamin D3 at doses 1.0 
and 2.5 mg/kg/day in combination with 17β-E2 have practically identical parameters 
of anxiety-like state as the OVX rats received only 17β-E2. Thus, this study failed 
to show any anxiolytic-like effects of vitamin D3 at doses of 1.0 or 2.5 mg/kg in the 
middle-aged OVX treated with 17β-E2. The present results might speculate that 
there exists some concurrent relation between 17β-E2 and vitamin D3 at doses of 
2.5 and 5.0 mg/kg/day for the brain structures implicated in the mechanisms of 
anxiety. In fact, additional application of 17β-E2 to the middle-aged OVX rats inter-
fered with anxiolytic-like action of vitamin D3 when it administered at doses 1.0 or 
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2.5 mg/kg. Thus, the effects of vitamin D3 administration in a combination with low 
dose of 17β-E2 on anxiety-like state of the middle-aged OVX rats are determined by 
dose of treatment.
ELISA assays demonstrated that administration of cholecalciferol only at doses 
of 2.5 and 5.0 mg/kg resulted in elevated 25-OH-VD3 levels in the blood serum 
of the middle-aged OVX rats with long-term absence of estrogen. Moreover, 
application of cholecalciferol at these doses with low dose of 17β-E2 induced more 
profound increase of 25-OH-VD3 levels in the blood serum of the middle-aged OVX 
rats. These data suggest that the different effects of cholecalciferol application in the 
middle-aged OVX rats with long-term absence of estrogen on anxiety-like behavior 
in the EPM and LDT did not associated with its effects on 25-OH-VD3 levels.
Biochemical analysis showed that administration of cholecalciferol at all doses 
alone or in a combination with 17β-E2 resulted in elevated 25-OH-VD3 levels in the 
blood serum of the old OVX rats with long-term absence of estrogen. Cholecalciferol 
administered alone at all doses similarly increased estradiol levels in the blood 
serum of the old OVX rats after long-term ovariectomy. On the other hand, only 
application of cholecalciferol at a dose of 1.0 mg/kg with low dose of 17β-E2 induced 
more profound increase of estradiol levels in the blood serum of the old OVX rats. 
Moreover, cholecalciferol in several doses failed to induce any changes in calcium 
concentrations in the blood serum of the old OVX rats given with solvent or 17β-E2.
These data suggest that the different effects of cholecalciferol application per 
se in the middle-aged and old OVX rats with long-term absence of estrogen on 
anxiety-like behavior in the EPM and LDT did not associated with its effects on 
estradiol, 25-OH-VD3 and calcium levels.
However, we can speculate that behavioral effects of cholecalciferol treatment 
with low dose of 17β-E2 in the EPM and LDT tests might connected with fluctua-
tions of estradiol levels in the blood serum of the middle-aged and old OVX rats. 
It is possible that specific sites of action involved in the anxiolytic-like effects of 
cholecalciferol that also modulated by estrogens are affected by the endocrine 
milieu that prevails at different period for the middle-aged and old female rats. 
Moreover, after a long-time absence of ovarian fluctuations an adaptive process 
may contribute to a better response for cholecalciferol administration at a dose of 
1.0 mg/kg in the old female rats and for cholecalciferol at a dose of 5.0 mg/kg in the 
middle-aged female rats.
The role of ovarian hormones in anxiety and stress sensitivity is of great inter-
est for women transitioning through menopause [37, 38]. Mood disorders during 
menopause could be partly due to loss of estrogen with menopause because estrogen 
is known to have neuroprotective effects on brain [39, 40]. Menopausal hormonal 
therapy (MHT) may improve the symptoms of affective-related state in people 
or decrease the risk of developing mood disturbances in older women, but this is 
unclear because in some studies MHT does not stop the development of anxiety-like 
symptoms in elderly postmenopausal women [41]. The exact role of estrogen still 
needs to be defined.
Menopause are also at higher risk of developing VD deficiency due to decreased 
dietary intake, less sun exposure, restricted outdoor activity and a decreased capac-
ity to produce enough calcitriol as a result of an age related decline in hydroxylation 
by kidneys [42–44].
Vitamin D3 is a hormone precursor which is transformed into 1,25-dihydroxyvi-
tamin D (1,25-(OH)2D3) in the liver and kidney [45]. Through decades, this active 
form of VD has been involved in the brain development and functions of the central 
nervous system (CNS) [46, 47]. Hormonal form 1,25(OH)2D3 enters the brain via 
the blood-brain barrier to act directly on cells containing its nuclear receptor, the 
VDR [48, 49].
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The presence of VD receptors (VDR) outside the skeletal system, enterocytes 
and renal tubular cells was confirmed in many cell types including immune cells, 
neurons, pancreatic cells, myocytes, cardiomyocytes, endothelium cells, which stress 
pleiotropic activity of VD [50, 51]. The active form of vitamin D is transferred to 
astrocytes where it can bind to VDR and initiate gene transcription or be inactivated 
when in excess [48, 49]. Alternatively, 1,25(OH)2D3 can induce autocrine or paracrine 
rapid non-genomic actions since all brain cell types express the other membrane 
receptor of VD [48]. It is possible that the behavioral effects of cholecalciferol are 
mediated by multiple target regions, including brain centers that are involved in the 
mechanisms of anxiety-like behavior. Regardless, it cannot presently exclude possible 
indirect effects of vitamin D3 on different neurotransmitter circuits. Further research 
is required to investigate the underlying mechanisms in its anxiolytic-like effects.
It is well-established both systemic effects of VD on calcium metabolism and 
neuroprotective effects of VD on the brain [52]. Low VD levels has been implicated 
in the pathophysiological mechanisms of cardiovascular diseases, depression, 
anxiety, cognitive disorders, obesity, metabolic syndrome, type 2 diabetes, vari-
ous types of cancer and immune disorders [10, 52]. According to Gaugris and 
co-workers [53], the prevalence of low VD levels appears to be high in postmeno-
pausal women. Additionally, the decline of estrogens after menopause decreases 
the activity of 1α-OHase, which results in lower synthesis of the active VD form 
[53, 54]. Application of vitamin D3 in specific periods of women’s life, seems to be 
of great importance, because it may reduce the risk of affective-related diseases 
during menopausal period [55–57]. However, the current data for vitamin D3 
application studies are very incomplete and need of more intensive investigations. 
The main point of question is to examine how the interaction between vitamin D3 
and estradiol might alter at specific periods of women’s life, and the impacts of such 
alterations elsewhere in the postmenopausal woman. VDR have been identified 
throughout the female reproductive tract [58, 59]. Some studies have demonstrated 
a direct modulation by VD of estradiol, estrone and progesterone production in 
human ovarian cells [60–62]. It could be supposed that estrogens and VD share 
similar targets of the brain to induce their anxiolytic-like effects. However, the 
behavioral manifestations of VD at various doses are completely different in the 
middle-aged and old OVX females. It is likely that VD acts through a various 
mechanisms that are sensitive in female rats of different age with long-term absence 
of ovarian hormones. Moreover, it is completely needed to understand the precise 
mechanisms of how VD treatment alone or in a combination with 17β-estradiol 
supplementation may affect women’s anxiety-related state.
These points illustrate how the current state of VD treatment research is incom-
plete and in need of more intensive research. Working toward uncovering how the 
interaction between VD and estradiol changes after menopause, and the implications 
of these changes elsewhere in the postmenopausal woman, is necessary for providing 
the most complete understanding of how VD treatment alone or in a combination 
with 17β-estradiol supplementation may affect women’s affective-related state.
VD as changes in VDR impact on various brain neurotransmitters, and thus sug-
gest a potential role of vitamin D in causing and redressing mood disorders [63]. It 
could be supposed, even though estrogens and cholecalciferol share similar targets 
on monoaminergic or another neurotransmitter system to induce their anxiolytic-
like effects, the behavioral manifestations of cholecalciferol are completely differ-
ent in the old OVX females. It is likely that cholecalciferol acts through a different 
mechanisms of action that is sensitive to the age of female rats with long-term 
absence of ovarian hormones.
In conclusion, the results of this study can be summarized as follows: all tested 
doses of cholecalciferol given alone are produced anxiolytic-like effects in the 
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EPM and LDT in the old OVX female rats; the one specific dose of cholecalciferol 
(1.0 mg/kg/day) in the old OVX rats and another one dose of cholecalciferol 
(5.0 mg/kg/day) in the middle-aged OVX rats are able to induce synergic anx-
iolytic-like effect in the EPM and LDT; effects of cholecalciferol on anxiety-like 
behavior in the middle-aged and old OVX rats after long-term absence of estrogen 
are dependent from absence or presence of additional hormonal treatment as 
17β-E2. Further investigations is to be addressed in relation to such issues: whether 
different effects of cholecalciferol on anxiety-like behavior are dependent from 
different age of rats, or whether different doses of cholecalciferol on anxiety-like 
behavior in OVX rats with different age rats might lead to negative versus positive 
effects. Further research, with properly designed experimental studies, is needed 
to test this hypothesis. In addition, further research is needed to elucidate the 
biochemical mechanism/(s) of cholecalciferol effects on the anxiety-like behavior 
and their physiological relevance for development of mood impairment at estrogen 
deficiency at aging. Furthermore, the mechanism by which cholecalciferol produces 
anxiolytic-like effect in the middle-aged and old OVX rats and the implications of 
this in brain function need to be investigated in future research. Moreover, further 
studies are needed to evaluate the association of VD with estrogen-related pathways 
and to conduct detail experiments together with biochemical studies of these 
subjects to verify the significance of this study.
5. Conclusions
The present data of the preclinical study indicates that chronic cholecalciferol 
at a dose of 5.0 or 1.0 mg/kg, s.c. treatment decreased anxiety-related behavior 
after impairment induced by long-term ovariectomy in the middle-aged and 
old female rats with long-term absence of estrogen, respectively. The data also 
indicate that the combination of cholecalciferol at a dose of 5.0 mg/kg and 17β-E2 
is more effective than 17β-E2 alone in the middle-aged OVX rats inducing more 
synergic anxiolytic-like effects in the EPM and LDT. Moreover, a combination of 
cholecalciferol at a dose of 1.0 mg/kg s.c. and 17β-E2 is more effective than 17β-E2 
alone in the old OVX rats inducing a more synergic anxiolytic-like effects in the 
EPM and LDT. Furthermore, this is the first study to show a beneficial effect of 
chronic cholecalciferol at dose of 1.0 mg/kg s.c. administration on anxiety-related 
states induced by long-term ovariectomy in the old female rats. Importantly, these 
results suggest that 17β-E2 administration interfered with anxiolytic-like action of 
cholecalciferol administered alone at doses of 2.5 or 5.0 mg/kg to the old OVX rats 
with long-term absence of estrogens. This work promotes more effective creating 
of the novel therapeutic targets and strategies for anxiety-like treatment in the 
middle-aged and old subjects with long-term estrogen deficiency.
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